Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock
Completed · Phase 4 · NCT05824767
Conditions: Septic Shock, Vasodilatory Shock
At a glance
- Research payments reported, 2025
- $48,200
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 42
About the trial
- Sponsor
- University of New Mexico (with La Jolla Pharmaceutical Company)
- Tested
- Angiotensin II (drug)
- Dates
- Started 2023-04-17; completion 2025-03-12
- Results posted
- Yes
This trial will be a randomized controlled single-center pilot trial comparing the use of angiotensin II versus standard-of-care (SOC) vasopressor therapy in adult patients with persistent vasodilatory shock despite moderate-dose norepinephrine, with a primary outcome of the ability of novel biomarkers (renin and DPP3) to predict blood pressure response to angiotensin II. Given our angiotensin II will be compared to SOC, this will be an unblinded study.
From ClinicalTrials.gov, last updated 2026-07-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
La Jolla Pharmaceutical Company reported $48,200 in research payments for this study in 2025 (5 payments).
Products named: Giapreza
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of New Mexico Health Sciences Center $48,200
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.